SCHEDULE: EcoR1 Capital Amends Apellis Pharma Stake
Schedule 13G Amendment
EcoR1 Capital, LLC and related entities filed an amended Schedule 13G, disclosing a 2.7% beneficial ownership stake in Apellis Pharmaceuticals, Inc. as of September 30, 2025.
Summary
- EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Apellis Pharmaceuticals, Inc. common stock.
- EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 3,447,156 shares, representing 2.7% of the class.
- EcoR1 Capital Fund Qualified, L.P. beneficially owns 3,219,256 shares, representing 2.5% of the class.
- The percentages are calculated based on 126,525,218 shares of Common Stock outstanding on October 23, 2025, as reported in Apellis Pharmaceuticals, Inc.'s Form 10-Q for the quarter ended September 30, 2025.
- The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine ownership disclosure and does not contain operational or financial performance data that would influence sentiment.
Positives
- A specialized healthcare investment firm, EcoR1 Capital, maintains a significant, albeit passive, stake in Apellis Pharmaceuticals, Inc., indicating continued interest in the company.
Negatives
- No specific negative information is disclosed in this routine ownership filing.
Risks
- This filing is an ownership disclosure and does not contain information regarding operational or financial risks of Apellis Pharmaceuticals, Inc.
Future Outlook
This filing is an ownership disclosure and does not contain forward-looking statements or guidance from the issuer or reporting persons regarding future performance.
Management Comments
- The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing reflects a routine disclosure by an institutional investor in the biotechnology sector, indicating a passive investment in Apellis Pharmaceuticals, Inc. It is common for investment funds to hold such stakes without seeking to influence control.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-23 | Date on which 126,525,218 shares of Common Stock were reported outstanding by the Issuer in its Form 10-Q. |
| 2025-11-14 | Date of signing and filing of the Schedule 13G Amendment No. 2. |
Keywords
Apellis Pharmaceuticals, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.